3 Topic Commentaries

FDA revises monitoring for SCLC therapy

• 

  Robert Daly, MD, MBA

  Thoracic medical oncology (lung cancer)

  •

  Memorial Sloan Kettering Cancer Center

  Thanks to technology like telehealth and remote monitoring of patients’ vital signs, We have the potential to help more patients — and make cancer care less disruptive to their lives.

  Source
• 

  Ryan D. Gentzler, MD

  Thoracic medical oncology (lung cancer)

  •

  University of Virginia Comprehensive Cancer Center (UVA Health)

  This treatment requires intensive monitoring and careful coordination among a large team of care providers,

  Source
• 

  Mariam Alexander, MD, PhD

  Medical oncology (lung and solid tumors)

  •

  MUSC Hollings Cancer Center, Medical University of South Carolina

  As a result, we used to turn away trials that required inpatient monitoring. But I felt this treatment was the future. If we couldn’t do it here, our patients would be at a serious disadvantage.

  Source